KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Capital Expenditures (2016 - 2026)

AbbVie has reported Capital Expenditures over the past 14 years, most recently at $329.0 million for Q4 2025.

  • Quarterly Capital Expenditures rose 13.06% to $329.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 24.64% year-over-year, with the annual reading at $1.2 billion for FY2025, 24.64% up from the prior year.
  • Capital Expenditures was $329.0 million for Q4 2025 at AbbVie, down from $381.0 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $381.0 million in Q3 2025 and troughed at $143.0 million in Q2 2022.
  • The 5-year median for Capital Expenditures is $209.0 million (2022), against an average of $222.4 million.
  • Year-over-year, Capital Expenditures tumbled 32.97% in 2021 and then skyrocketed 53.01% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $187.0 million in 2021, then grew by 13.9% to $213.0 million in 2022, then decreased by 3.76% to $205.0 million in 2023, then surged by 41.95% to $291.0 million in 2024, then increased by 13.06% to $329.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Capital Expenditures are $329.0 million (Q4 2025), $381.0 million (Q3 2025), and $269.0 million (Q2 2025).